Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, whether medicines funded under the Innovative Medicines Fund will be included in the calculation of that company's rebate under the Voluntary Pricing Scheme for Branded Medicines (VPAS).

The Innovative Medicines Fund (IMF) builds on the successful Cancer Drugs Fund and will support patient access to the most promising new medicines while further evidence is collected on their use to address clinical uncertainty.

Funding for the IMF is allocated from NHS England budgets. Unless specifically exempt under scheme rules, sales of products within the IMF are included in measured sales when calculating sales growth used to set the voluntary scheme for branded medicines pricing and access payment percentage each year and included in eligible sales used to calculate the amount owed by the relevant scheme member each quarter.